Stocks making the biggest moves premarket: Moderna, Lowe's, Estee Lauder & more
Moderna and Merck shares surged 57% and 6% respectively after positive cancer vaccine trial results. Marvell Technology rose 11% following a $12B Google investment deal. Keysight Technologies gained 2% on better-than-expected Q3 results. Lowe's fell 2% after lowering full-year guidance. Target declined 1.5% despite revenue beats. La-Z-Boy dropped 17% on weak Q1 earnings. Mercury Systems slid 9% on lower revenue forecasts. Toll Brothers rose 1% on Q3 earnings beats. Estee Lauder gained 7% after Q
How this was made
The 30-second read
Why it matters
The article provides first‑day earnings and partnership disclosures that drive immediate price reactions, offering traders actionable insights for short‑term positions.
Market read
Multiple large‑cap stocks experienced double‑digit moves on fresh earnings or partnership news, making the article highly relevant for intraday traders.
What to watch
Potential regulatory delays for the cancer vaccine and the long‑term impact of Google's stake in Marvell.
Background
Premarket roundup highlighting the biggest price moves and earnings releases for a set of U.S. listed companies.
Ticker impact
Moderna stock surged 57% premarket after positive late‑stage trial results for a personalized cancer vaccine.
Further upside if data leads to FDA submission.
Phase‑3 data is material and the move is double‑digit on the day of release.
Merck jumped ~6% premarket following the same positive cancer‑vaccine trial news.
Potential continued rally pending regulatory path.
Significant price move on fresh clinical data.
Marvell Technology rose >11% after announcing Google will buy a $12 billion stake to develop custom chips.
Likely further upside as partnership details unfold.
Large capital infusion and strategic tie‑up disclosed for the first time.
Keysight Technologies up 2% after Q3 earnings of $3.07 EPS beat $2.48 consensus and revenue $1.85 bn beat $1.75 bn.
Modest upside may continue on earnings momentum.
First‑day earnings release with beat on both metrics.
Target fell 1.5% despite better‑than‑expected Q2 revenue and a $752 m net‑earnings boost from tariff refunds.
Sideways to slight downside pending further guidance.
Earnings data released; market reaction modest.
La‑Z‑Boy dropped ~17% as Q1 adjusted EPS fell to $0.43 and revenue guidance missed consensus.
Further downside likely if outlook not improved.
Large price move on fresh earnings miss.
Mercury Systems slid >9% after FY revenue guidance of ~$1.1 bn missed $1.05 bn consensus and EPS missed by one cent.
Continued weakness expected.
First‑day guidance miss with notable price decline.
Toll Brothers rose just over 1% after Q3 earnings of $2.97 EPS and revenue $2.65 bn beat estimates.
Potential incremental gain.
Earnings beat disclosed; market reaction limited.
Market effects
Biotech, pharma, semiconductors and consumer retail sectors see mixed earnings impacts.
U.S. equities influenced by broad premarket moves across multiple sectors.
Limited to U.S. listed companies; no direct global macro effect.
Counterpoint
Some stocks (e.g., Lowe's, Target) may be oversold despite earnings beats, offering buying opportunities.
Key entities
- CompanyModerna
Biotech firm with positive cancer vaccine trial data.
- CompanyMarvell Technology
Chipmaker receiving a $12 bn investment from Google.
